FORMULATION AND IN VITRO EVALUATION OF SALBUTAMOL SULPHATE AND THEOPHYLLINE EXTENDED-RELEASE TABLETS USING MODIFIED POLYMERS by Goyal, Naveen & Kumar, Anil
 
Original Article 
FORMULATION AND IN VITRO EVALUATION OF SALBUTAMOL SULPHATE AND 
THEOPHYLLINE EXTENDED-RELEASE TABLETS USING MODIFIED POLYMERS 
 
NAVEEN GOYALa, ANIL KUMARb* 
aDepartment of Pharmacognosy, Roorkee College of Pharmacy, Roorkee, Uttarakhand, India, bDepartment of Pharmaceutics, Roorkee 
College of Pharmacy, Roorkee, Uttarakhand, India 
Email: anildost78@gmail.com 
Received: 09 May 2018 Revised and Accepted: 07 Jul 2018 
ABSTRACT 
Objective: The main objective of this research work was to design, prepare and evaluate extended release (ER) tablets of anti-asthmatic drugs 
(salbutamol sulphate and theophylline) by direct compression method using diverse ratios of hydroxypropyl methylcellulose (HPMC K100M) and 
ethyl cellulose (EC) along with some other excipients.  
Methods: Extended-release matrix tablets of salbutamol sulphate and theophylline were successfully fabricated by direct compression method and 
coded the formulations as F1 to F7 depending on the ratios of modified polymers. The core tablets composed of hydrophilic polymers of various 
ratios that allow the discharge of drugs at a controlled rate after coming in contact with the aqueous medium. The designed tablets were subjected 
to various assessment parameters i.e. friability test, hardness test, drug content consistency and In vitro dissolution tests. 
Results: Prepared formulations were subjected to various assessment parameters and the findings obtained were within the prescribed limit. To 
perform the in vitro drug dissolution tests of fabricated tablets, the calibration plots of pure drugs using various solvents i.e. 0.1N HCl, phosphate 
buffer (pH 6.8) and distilled water were plotted. Dosage forms F1-F7 containing ethyl cellulose and HPMC K100M in various concentration 
demonstrates the prolonged medications discharge for up to 8 h, among these formulations, F6 shows 95.32±0.24 % for salbutamol sulphate and 
94.19±0.39 % for theophylline release at the end of 8 h. This finding reveals that a particular window of concentrations of ethylcellulose and HPMC 
K100M was capable of providing prolonged drugs discharge. 
Conclusion: The results obtained in this research work clearly showed a promising potential of extended-release tablets containing a specific ratio of HPMC 
K100M and ethylcellulose as a release rate controlling polymers for effective treatment of asthma and chronic obstructive pulmonary diseases (COPD). 
Keywords: Salbutamol sulphate, Theophylline, HPMC K100M, Ethylcellulose and Extended-release tablets 




Tablets have been the most preferred oral dosage form for the 
patients suffering from chronic diseases like bronchial asthma, 
chronic bronchitis and chronic obstructive pulmonary diseases 
(COPD) because of low-cost therapy and ease of administration [1, 
2]. The traditional tablets provide only a single and transient release 
of the drug. The pharmaceutical effect has only seen for the time 
duration in which the concentration of the drug remains within the 
therapeutic range that can be best achieved with ER tablets [3]. The 
significance of administering single-dose extended-release tablet 
that has discharged over an extended timeframe instead of multiple 
doses becomes the area of interest for the formulation designing 
scientists in the Pharmaceutical industry [4]. The oral prolonged 
discharge dosage form has been prepared for those medications that 
are comfortably absorbed from the gastrointestinal tract (GIT), have 
a short half-life and eliminated quickly from the bloodstream [5].  
The terms sustained action, sustained discharge, controlled 
discharge, timed release, prolonged action, depot, extended action 
and repository formulations have been used to represent the novel 
drug delivery system (NDDS) and formulated to get an extended 
therapeutic effect by continuously discharging drug over a 
prolonged time period after administration of a single dose [6]. 
There might be several other reasons also for the attractiveness of 
these dosage forms viz. provides enhanced bioavailability of 
medication, lessening in the recurrence of administration to extend 
the timeframe of effective blood levels, reduces the fluctuation of the 
peak-trough level and adverse effects and possibly enhances the 
particular distribution of the medication [7].  
Salbutamol sulphate and theophylline drugs show the synergistic 
effect in terms of producing prolonged bronchodilation for the 
treatment of reversible bronchospasm and COPD [8]. The short half-
life of salbutamol sulphate and theophylline (4 to 6 hr) drugs 
increases the frequency of drug administration as an immediate 
release dosage form but makes them the best candidates for the 
design of extended-release tablets [9]. The present study aims to 
formulate, fabricate and evaluate the once-daily dose of extended-
release matrix tablets using hydrophilic polymers, such as HPMC 
K100M and ethylcellulose in different ratios. 
MATERIALS AND METHODS 
Materials 
The drugs salbutamol sulphate and theophylline were obtained as a 
gift sample from Elegant Drugs Pvt. Ltd., Karnataka and Koves India 
Ltd. Chennai. Polymers HPMC K100M and ethylcellulose were 
purchased from Evonik Degussa and Titan Biotech Ltd., Bhiwadi, 
Rajasthan. All used reagents and chemicals were procured from 
commercial stores and also of a good analytical grade.  
Methodology 
Establishment of the calibration data 
In order to conduct the in vitro drug dissolution studies, the calibration 
tables containing data of pure drugs using different solvents viz. 0.1N 
HCl, phosphate buffer (pH 6.8) and distilled water were constructed. 
Calibration data has been used to find out the concentration of 
unknown sample taken from the dissolution media during dissolution 
studies at an equal interval of time. For this, 10 mg of salbutamol 
sulphate was accurately weighed and transferred into a 10 ml 
volumetric flask containing approximately 5 ml of 0.1 N HCl. Flask was 
then gently shaken to dissolve its contents and volume was finally 
made up to 10 ml using the same solvent and was labeled as stock 
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solution “A”. 1 ml of this solution was pipetted out in another 
volumetric flask and volume was made up to 10 ml with 0.1N HCl in 
order to obtain the resulting solution of 100 µg/ml, it was then labeled 
as stock solution "B". Finally by using stock solution "B", solutions of 
various concentrations such as 2, 4, 6, 8, 10, 12 µg/ml were prepared. 
0.1N HCl was taken as blank and absorbance of different dilutions 
were taken at 277 nm (nanometer) similarly, standard plots of pure 
salbutamol sulphate were also constructed at the same λmax using 
phosphate buffer and distilled water. 
Similarly, the same procedure was followed for the drug 
theophylline to prepare the dilutions of different concentrations i.e. 
2, 4, 6, 8, 10, 12 µg/ml with all three solvents (0.1 N HCl, Phosphate 
buffer and distilled water). The absorbance of all dilutions for 
theophylline was taken at 271 nm λmax [10, 11]. 
Table 1 and 2 enlisted the standard curve data of salbutamol 
sulphate and theophylline in 0.1N HCl, phosphate buffer (pH 6.8) 
and distilled water respectively. 
 
Table 1: Standard plot data of salbutamol Sulphate in 0.1N HCl 
S. No. Conc. (µg/ml) Average absorbance 
0.1N HCl Phosphate buffer (pH 6.8) Distilled water 
1 2 0.1213 0.1128 0.1191 
2 4 0.2423 0.2374 0.2312 
3 6 0.3689 0.3496 0.3742 
4 8 0.5065 0.4302 0.5012 
5 10 0.6258 0.5380 0.6243 
6 12 0.7371 0.6529 0.7491 
 
Table 2: Standard plot data of theophylline 
S. No. Conc. (µg/ml) Average absorbance 
0.1N HCl Phosphate buffer (pH 6.8) Distilled water 
1 2 0.1104 0.1121 0.1072 
2 4 0.2107 0.2197 0.2088 
3 6 0.2989 0.3221 0.3316 
4 8 0.3952 0.4296 0.4526 
5 10 0.5274 0.5285 0.5979 
6 12 0.6196 0.6313 0.6882 
 
Preparation of extended-release tablets 
ER tablets of salbutamol sulphate and theophylline (F1-F7) were 
fabricated by developing the formulae utilizing variable 
concentrations of two polymers viz. HPMC K100M and ethylcellulose 
as shown in table 3. The concentrations of salbutamol sulphate and 
theophylline were kept consistent for all groups of formulations. 
Salbutamol sulphate, theophylline and various excipients were 
weighed precisely apart from magnesium stearate and talc, after 
that blended in a mortar with a pestle for 10-15 min. After the 
blending of medications with excipients, the required quantity of 
talc and magnesium stearate was included and additionally blending 
was done for 4-5 min. The gross weight of every tablet was kept at 
250 mg [12, 13]. 
 
Table 3: Formulations of ER tablets of salbutamol sulphate and theophylline 
Ingredients (mg) Formulation code 
F1 F2 F3 F4 F5 F6 F7 
Salbutamol sulphate 4 4 4 4 4 4 4 
Theophylline 100 100 100 100 100 100 100 
HPMC K100M 40 50 60 - - 40 50 
Ethylcellulose - - - 60 75 60 75 
Lactose 100 90 80 80 65 40 15 
Magnesium stearate 2 2 2 2 2 2 2 
Talc 4 4 4 4 4 4 4 
Total weight 250 250 250 250 250 250 250 
 
Evaluation of extended-release tablets 
Prepared formulations (F1-F7) were assessed for different 
parameters like hardness, friability, content uniformity and in vitro 
dissolution test. 
Friability 
To assess the capability of the tablet to withstand wear and tear in 
packing, handling and transporting, friability test was done by Roche 
Friabilator. Pick randomly twenty tablets and weight (WO) and were 
subjected to the joined impact of wearing down and shock by utilizing a 
plastic chamber (25 rpm) dropping the tablets at a separation of 6 inches 
with each revolution, operated for 100 revolutions. Each tablet was 
dusted and reweighed (W) after completion of 100 revolutions. The % 
friability was calculated using this formula [14]. 
Friability % =  
WO − W
WO
× 100 … eq 1 
Tablet hardness 
This represents the pressure which is required to crush the tablet. 
Monsanto hardness tester was used to determine the hardness of 
prepared tablets. The average hardness and standard deviation 
were determined and the hardness of 4 kg is considered to be least 
for a satisfactory tablet [15, 16]. 
Uniformity of drug content 
Assay of ER tablets of salbutamol sulphate and theophylline was 
performed in distilled water to find out the number of drugs present 
in one tablet. For this 2 tablets were weighed and powdered in a 
glass mortar and 250 mg of the powder equivalent to 4 mg of 
salbutamol sulphate and 100 mg of theophylline was placed in two 
separate 100 ml volumetric flasks and dissolved in 100 ml water. 
The resulting solution was filtered and absorbance was recorded at 
λmax 277 nm for salbutamol sulphate and λmax 271 nm for 
theophylline using UV visible spectrophotometer. The concentration 
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of medications in milligram per millilitre was calculated from 
standard calibration plots of drugs [17, 18]. 
In vitro drug release studies 
In vitro release of salbutamol sulphate and theophylline from ER 
tablets was obtained separately by using USP type II (Paddle 
Type) dissolution apparatus in 900 ml of phosphate buffer of pH 
6.8 at the constant temperature of 37 °±0.5 °C at 50 rpm. 
Aliquots (5 ml) of the solutions were taken out from the 
dissolution apparatus at various time intervals and replaced 
with fresh dissolution medium to maintain the sink condition. 
Samples were filtered and the absorbance of these solutions was 
observed by using a double beam ultra-violet spectrophotometer 
at 277 nm and 271 nm for salbutamol sulphate and theophylline 
respectively against fresh phosphate buffer solution as the blank 
[19, 20%	]. 
RESULTS AND DISCUSSION 
RESULTS 
Observations of evaluation of various parameters are depicted in 
table 4, 5 and 6. Table 5 and table 6 represents the % cumulative 
drug release versus time profile of in vitro dissolution studies for 
both drugs (salbutamol sulphate and theophylline). 
 







Drug content (%) Thickness (mm) 
mean±SD Salbutamol sulphate Theophylline 
F1 5.5±0.40 0.49±0.068 249.6±3.32 95.57±0.560 97.42±0.42 4.15±0.11 
F2 5.8±0.35 0.46±0.016 250.4±2.25 99.67±1.06 95.88±0.36 4.27±0.10 
F3 5.1±0.21 0.30±0.073 248.7±2.31 97.51±0.66 99.65±0.71 4.26±0.07 
F4 5.3±0.24 0.32±0.065 248.7±2.31 98.49±1.34 99.18±0.38 4.19±0.05 
F5 5.4±0.21 0.41±0.064 249.5±2.31 97.41±0.87 97.48±0.65 4.28±0.11 
F6 5.7±0.11 0.48±0.091 252.3±2.68 101.39±0.42 100.11±0.31 4.22±0.13 
F7 5.3±0.14 0.41±0.072 248.5±2.49 102.23±0.82 99.68±0.43 4.18±0.08 
All values are mean±SD of three determinations 
 
Table 5: In vitro drug release profile of salbutamol sulphate 
Time (h) F1 F2 F3 F4 F5 F6 F7 
0 0 0 0 0 0 0 0 
1 32.50±0.33 26.49±0.83 18.20±0.53 09.20±0.53 08.56±0.29 14.22±0.80 11.87±0.66 
2 46.41±0.34 36.50±0.62 25.69±0.40 13.69±0.40 13.31±0.58 28.56±0.84 15.21±0.61 
3 57.49±0.62 44.24±0.77 39.38±0.82 21.38±0.82 20.86±0.22 42.01±0.60 22.31±0.24 
4 72.65±0.13 59.50±0.53 51.42±0.19 27.42±0.19 27.77±0.49 57.59±0.62 28.29±0.47 
5 99.03±0.56 71.34±0.73 65.29±0.07 36.29±0.07 37.54±0.91 75.52±0.73 38.05±0.84 
6 99.17±0.63 81.29±0.80 76.18±0.73 49.18±0.73 45.38±0.37 84.09±0.96 52.73±0.09 
7 99.12±0.78 99.08±0.44 85.51±0.78 60.51±0.78 50.11±0.47 92.44±0.38 61.24±0.67 
8 99.34±0.45 99.85±0.61 89.44±0.91 71.44±0.91 60.32±0.27 95.32±0.24 78.06±0.42 
12 99.42±0.35 99.59±0.57 91.19±0.65 71.19±0.65 71.22±0.31 96.35±0.54 84.16±0.65 
24 99.48±0.18 99.55±0.51 92.67±0.87 73.67±0.87 71.62±0.27 97.99±0.55 86.01±0.69 
 
 
Fig. 1: Graphical representation of dissolution profile of salbutamol sulphate (F1-F7) 
 
Table 6: In vitro drug release profile of theophylline 
Time(h) F1 F2 F3 F4 F5 F6 F7 
0 0 0 0 0 0 0 0 
1 28.06±0.39 21.80±0.22 17.66±0.61 09.11±0.53 07.55±0.63 12.49±0.78 10.16±0.18 
2 43.73±0.63 32.08±0.21 23.05±0.47 14.62±0.73 13.09±0.77 27.03±0.22 14.19±0.45 
3 54.67±0.45 39.11±0.42 37.66±0.29 23.25±0.54 19.36±0.52 39.66±0.03 20.42±0.62 
4 68.91±0.32 57.38±0.76 48.01±0.35 27.33±0.61 27.56±0.35 55.84±0.18 26.17±0.11 
5 96.55±0.43 69.65±0.88 64.97±0.46 35.78±0.23 35.45±0.21 73.15±0.36 37.72±0.86 
6 98.84±0.56 77.03±0.37 74.38±0.75 45.63±0.72 45.76±0.55 81.36±0.82 52.36±0.28 
7 98.34±0.67 96.48±0.62 82.86±0.44 49.69±0.57 51.88±0.56 90.47±0.42 59.15±0.10 
8 98.11±0.31 97.64±0.55 86.48±0.39 58.66±0.11 59.44±0.34 94.19±0.39 73.04±0.62 
12 98.12±0.81 97.36±0.58 89.66±0.21 69.02±0.26 68.21±0.36 94.68±0.43 80.73±0.51 
24 98.36±0.44 97.63±0.70 89.54±0.11 77.19±0.27 75.48±0.39 94.36±0.12 81.33±0.14 
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Fig. 2: Graphical representation of dissolution profile of theophylline (F1-F7) 
 
DISCUSSION 
Prepared formulations were subjected to various assessment 
parameters and the findings obtained were within the limits which are 
depicted in table 4. The hardness of all the tablets was within a range 
of 5.1±0.12 to 5.8±0.32 kg/cm2. Weight loss of all tablets in friability 
test lay in a range of 0.30±0.098 to 0.49±0.057 %. The % drug content 
for various tablet formulations was in the range from 95.57±0.560 to 
102.23±0.82 % for salbutamol sulphate and 95.88±0.36 % to 
100.11±0.31 % for theophylline. The F-6 containing HPMC K100M and 
ethylcellulose (2:3 ratios) was selected as the optimum formulation on 
the basis of the results of in vitro dissolution tests. It is seen that at the 
end of 8 hr, 95.32±0.24% salbutamol sulphate and 94.19±0.39 % 
theophylline were released from the formulation. 
CONCLUSION 
The extended-release tablets of salbutamol sulphate and 
theophylline using specific ratio (2:3) of HPMC K100M and 
ethylcellulose can be successfully fabricated by direct compression 
method. Concentrations and ratios of used polymers i.e. HPMC 
K100M and ethylcellulose can affect the release of the drugs from 
the dosage form. Among the prepared batches of ER tablets based on 
performance with respect to friability, hardness, uniformity of drug 
content and in vitro % cumulative drug release studies, F6 delivers 
the best results. The formulation F6 discharge required loading dose 
concentration and maximum percentage cumulative drugs release 
over a period of 8 h which is 95.32±0.24% for salbutamol sulphate 
and 94.19±0.39% for theophylline. 
It can be concluded from the observations that formulation F-6 has 
achieved the objectives of extended-release formulations i.e. patient 
convenience by reducing dosing frequency, reduction in toxicity, 
enhanced effectiveness of the drug by localization at the site of 
action and cost-effectiveness as an ER once daily dosage form. 
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